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Abstract 
 
Purpose. Conflicting evidence indicates HIV-seropositivity to influence the outcome of patients with 
hepatocellular carcinoma (HCC), a leading cause of mortality in people with HIV. We aimed to verify 
whether HIV affected the overall survival (OS) of patients with HCC independent of treatment and 
geographic origin.  
Patients and Methods: We designed an international multi-cohort study of HCC patients who did not 
receive any anticancer treatment accrued from four continents. We estimated the effect of HIV-
seropositivity on patients’ OS while accounting for common prognostic factors and demographic 
characteristics in uni- and multi-variable models.  
Results: A total of 1588 patients were recruited, 132 of whom were HIV-positive. Most patients 
clustered within Barcelona Clinic Liver Cancer (BCLC) C/D criteria (n=1168, 74%), Child-Turcotte-Pugh 
(CTP) Class B (median score 7, IQR 3). At HCC diagnosis the majority of HIV-positive patients (n=65, 
64%) had been on anti-retrovirals for a median duration of 8.3 years (IQR 8.59) and had median CD4+ 
cell counts of 256 (IQR 284) with undetectable HIV RNA (n=68, 52%). OS significantly reduced 
throughout BCLC stages 0-D (16, 12, 7.5, 3.1 and 3 months, p<0.001). Median OS of HIV-positive 
patients was half that of HIV-uninfected counterparts: 2.2 months, (bootstrap 95%CI  1.2-3.1) versus 
4.1 months (95%CI 3.6-4.4). In adjusted analyses HIV-seropositivity increased the hazard of death by 
24% (p=0.0333) independent of BCLC (p<0.0001), CTP (p<0.0001), alpha-fetoprotein (AFP) 
(p<0.0001), geographical origin (p<0.0001) and male gender (p=0.0016). Predictors of worse OS in 
HIV-positive patients included CTP (p=0.0071) and AFP (p<0.0001). 
Conclusions. Despite adequate antiretroviral treatment, HIV-seropositivity is associated with 
decreased survival in HCC independent of stage, anti-cancer treatment and geographical origin. 
Mechanistic studies investigating the immuno-biology of HIV-associated HCC are urgently required. 
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Introduction. 
 
Hepatocellular carcinoma (HCC) accounts as the third cause of cancer-related mortality on a global 
scale1. As a recognised complication of liver cirrhosis, which pre-dates the onset of cancer in >80% of 
the incident cases, HCC is characterised by a wide prognostic heterogeneity due to the mutual influence 
of aetiology and severity of underlying chronic liver disease over the extent of spread of malignancy2. 
In people living with HIV (PLHIV), the high prevalence of co-infection with Hepatitis B (HBV) and C virus 
(HCV) has made HCC a rapidly increasing cause of morbidity and mortality, currently accounting for 
40% of liver-related deaths3.  
The relative contribution of HIV to the pathogenesis and prognosis of HCC has been the focus of intense 
debate. Mechanistic evidence suggests HIV-mediated impairment of anti-viral CD4+ and CD8+ T-cell 
responses to facilitate an accelerated progression of chronic liver disease to fibrosis and, ultimately, 
malignancy4.  
However, more recent evidence has highlighted how other factors including increased oxidative stress 
from combination anti-retroviral therapy (cART)5, HIV-associated gut dysbiosis6 and the high 
prevalence of excessive alcohol intake in this patient population7 might exert a synergistic carcinogenic 
role independently from the achievement of immune-reconstitution by optimal HIV control. 
Clinical studies have been fairly inconsistent in addressing the question whether HIV infection might 
worsen the clinical course of HCC, with some providing null results and other suggesting evidence of 
association 8-10. The reasons behind the non-uniform conclusions as to this prognostic relationship are 
to be found in the low quality of the available evidence, mostly flawed by the retrospective, single-center 
design of the majority of studies 11. An important source of bias that affects the currently available 
evidence emerges from the geographic diversity in the provision of active anti-cancer treatment, which 
can in turn lead to profound differences in clinical outcomes. 
The marked heterogeneity in survival outcomes within each Barcelona Clinic Liver Cancer (BCLC) 
stage is a renowned feature of HCC12,13 and is even broader in PLHIV, where attainment of long-term 
HIV control, polypharmacy, socio-economic factors might influence access and eligibility to treatment, 
hence influencing patients’ survival independently from any true immuno-biologic effect of HIV14. 
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Understanding whether HIV carries an independent effect on the clinical history of HCC irrespective of 
treatment is an important unmet need, with significant ramifications in the definition of screening, 
diagnosis and treatment algorithms personalised to the needs and clinical features of this patient 
population11.    
To address this issue and overcome the limitations of previous studies, we designed this large 
collaborative global study including patients from cohorts from four continents. As a primary objective, 
we aimed to estimate the effect of HIV status on overall survival of untreated HCC patients while 
accounting for common prognostic factors. As a secondary objective, we also aimed to characterise 
prognostic factors among a subset of HIV+ patients with untreated HCC. 
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Methods. 
Study population. 
We established a global consortium of tertiary referral centers located in North and South America, 
Europe and to access prospectively collected cohorts of HIV+/HIV- patients with untreated HCC (Figure 
1). This multicenter effort led to accumulation of >1500 patients, resulting in the largest observational 
investigation on the effect of HIV infection among HCC patients conducted to date. 
Consecutive patient data were collected as part of routine clinical care.  Patients were not selected 
amongst clinical trial participants. HCC diagnosis was based on imaging or by histologic criteria 
according to international guidelines15.  
The Liver Cancer in HIV dataset study identified all patients diagnosed with HCC on a background of 
HIV infection in 44 referral centers providing specialist multidisciplinary care for HIV and HCC across 9 
countries including United States, Canada, Brazil, Argentina, Germany, Spain, United Kingdom, Italy 
and Australia. Consecutive referrals in the period between 1992 and 2016 were collected in a joint 
database as part of an international research consortium using electronic case report forms. At the last 
database update a total of 387 HIV-positive patients were identified16, which were merged with a 
separate dataset of 226 HIV-negative controls from four centers in the United States17. 
The ITA.LI.CA. dataset is a multi-center Italian collaborative network that has, to date, curated and 
prospectively maintained a dataset of >5000 consecutive patients evaluated in 24 tertiary referral 
centers for the assessment and treatment of HCC between years 1988-2012. Before statistical analysis, 
consistency of data was checked by the ITA.LI.CA. study coordinator (F.T.). Outcomes pertaining to a 
proportion of the patients presented here have been published in 201518. 
As a separate cohort, we assessed for eligibility 1470 patients with HCC that were diagnosed at the 
Department of Gastroenterology and Hepatology in the Singapore General Hospital, a tertiary-level 
medical center in Singapore and listed into a prospectively-maintained HCC registry since January 
198819. 
The primary clinical endpoint of the study was overall survival (OS), calculated from the date of 
diagnosis to the date of death and/or last follow-up. Out of the initial sample of 1590 patients, we 
removed 1 patient with unclear follow-up status and 1 patient with age <18 years. 
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In the full dataset of 1588 patients, we reconstructed demographic data, complete blood count including 
liver function tests, alpha-fetoprotein (AFP) and the international normalised ratio value for prothrombin 
time from electronic medical records. We staged patients using computerized tomography and/or 
magnetic resonance imaging as clinically required to derive the number of focal hepatic lesions and 
maximum tumour diameter detected during contrast enhancement. Computation of Child-Turcotte-
Pugh (CTP) functional class and Barcelona Clinic Liver Cancer (BCLC) stage followed standard pre-
published methodology20.  
We further characterised the subset of 132 HIV+ patients in terms of prior antiretroviral treatment, time 
from HCC to cART initiation, CD4+ T cells count, HIV viral load, hepatitis antigens and antibodies, and 
risk factors for HIV infection. 
The study protocol was approved by the Institutional Review Board/Ethics Committee in each 
participating institution and was conducted in accordance with the Declaration of Helsinki. 
 
 
Statistical analysis. 
We explored the distribution of continuous variables with median and interquartile range (IQR) and 
tested differences in medians using Mann-Whitney tests. We tabulated categorical variables factors 
and tested for differences in proportions using Pearson’s Chi-squared tests. We plotted the overall 
survival (OS) function by HIV status and potential prognostic factors using Kaplan-Meier curves. Prior 
to conducting Cox regression analyses, we checked the proportional-hazards assumption with log-
likelihood ratio tests of relevant predictors over time-bands. There was no evidence of violation at the 
5% level of the proportional-hazards assumption for the main predictor (HIV status, p=0.0870). For the 
predictors for which the proportional hazards assumption did not hold, we explicitly accounted for time-
dependent effects by adding interaction terms with time-bands in all regression analyses21. 
We imputed missing data using a multiple imputation with chained equations (MICE) approach, 
assuming that the data were missing at random. Details are included in the Supplementary Methods. 
To select the main prognostic factors, we applied a backward selection algorithm on the imputed 
datasets. Details are available in the Supplementary Methods. In the full dataset (N=1588), backward 
selection identified the following prognostic factors associated with OS at the 5% significance level: 
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HIV, gender, BCLC stage, CTP class, log-transformed AFP, and continent (a binary variable coded as 
North/South America and Asia vs. Europe). In the subset of HIV+ patients (N=132), two prognostic 
factors were associated with OS: CTP class, log-transformed AFP. We re-added common prognostic 
factor for HCC and HIV so that the final model for the subset of HIV+ patients included: CTP class, log-
transformed AFP, BCLC stage, HIV viral load, and CD4+ concentration. 
All reported p-values are two-sided. We carried out all analyses in R v.3.4.4 with the following packages: 
survival v.2.42, mice v. 3.0.0, and ggplot2 v.2.2.1. 
 
Results. 
 
Baseline Patient Characteristics. 
A total of 132 HIV+ and 1456 HIV- patients were included in the study. Baseline features of the study 
cohort, stratified according to HIV-seropositivity are presented in Table 1. HIV+ patients were on 
average younger (52.9 versus 66 years, p<0.0001), more commonly male (94.7 versus 81.9%, 
p=0.0003) and had higher prevalence of HCV-related chronic liver disease (78 versus 37.1%, p<0.0001) 
compared to HIV- patients. Staging by BCLC criteria (p=0.93) and liver functional reserve by CTP class 
(p=0.34) were not different across groups, however HIV+ patients had lower albumin (31 versus 29 g/L, 
p<0.0001) and higher ALT (56 vs 47, p=0.0014) and AST (128 versus 95, p=0.0005). The majority of 
patients had a performance status (PS) of 1 (n=534, 33.6%) and classified within CTP class B criteria 
across HIV- and HIV+ (median score 7, IQR 3). None of the HCV-infected patients from the ITA.LI.CA. 
or Singapore General Hospital datasets had previously been successfully treated for HCV.  In terms of 
anti-HBV treatment, 17 HBV-carriers (2.4%) from Singapore and the entirety of Italian patients with 
chronic HBV (16% of the ITA.LI.CA. dataset) were on nucleoside analogue therapy. 
In the HIV+ subset, 103 patients (78%) had HCV infection. Three patients had received treatment 
(2.9%) with interferon-based regimens prior to HCC diagnosis, all of whom were non-responders. HCV 
genotype was available in 53 patients (40.2%), 45 of whom (84.9%) were of genotype 1, 3 (5.7%) of 
genotype 2, and 5 (9.4%) of genotype 3. HCV RNA levels at the time of HCC diagnosis were available 
in 60 patients (45.5%), with 52 (86.7%) showing evidence of detectable viraemia. In the 33 patients with 
HBV-associated HCC (25%), 12 (36.4%) had evidence of detectable HBV DNA levels at HCC 
diagnosis, and 13 had received treatment for HBV infection (39.4%). The majority of HIV patients were 
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on cART (n=85, 64.4%) with a median duration of treatment of 8.3 years prior to the diagnosis of HCC. 
Most patients had undetectable HIV viral load at the time of HCC diagnosis (n=68, 51.5%) and CD4 
counts >200 cells/mm3 (n=71, 53.8%). The most prevalent risk factor for HIV infection was intravenous 
drug use (50%). 
 
The relationship between HIV and the survival of HCC. 
Kaplan Meier curves (Figure 2) revealed strong evidence of unadjusted lower survival for HIV+ patients 
compared to HIV- participants in the full sample of 1588 HCC patients (log-rank p<0.0001). Median OS 
for the whole study cohort was 4 months (bootstrap 95% confidence interval [CI] 3.8 to 4.1 months) with 
Barcelona Clinic Liver Cancer (BCLC) stage-specific median survivals of 16, 12, 7.5, 3.1 and 3 months 
for stages 0, A, B, C, and D respectively. At the time of analysis, 1428 patients (89.9%) had died. In the 
HIV+ cohort, no deaths could be attributed to HIV infection. 
After adjustment for common prognostic factors and multiple imputation of missing data, HIV infection 
was independently associated to 24% greater hazard of death (95%CI 2% to 52%; p=0.0333) (Table 
2A). Other prognostic factors independently associated with OS were male gender (p=0.0016), BCLC 
stage, CTP class, alpha-fetoprotein (AFP), and geographical origin (all p<0.0001). As expected, the 
adjusted effects estimated in complete-case analyses (Supplementary Table 1) were similar in size 
and direction compared to multiple imputation analysis. 
 
Prognostic factors for overall survival in HIV-associated HCC. 
In the subset of 132 patients with HIV infection, multivariable analyses after multiple imputation revealed 
two prognostic factors independently associated to OS: AFP (Hazard ratio [HR] 1.18; 95%CI 1.09 to 
1.28; p<0.0001) and CTP class C vs A (HR 2.78; 1.31 to 5.91; p=0.0079). There was no evidence of 
association with OS for BCLC stage, CTP class B vs A, CD4 count, viral load and geographical origin. 
These results were in line with those obtained from complete-case analyses (Supplementary Table 
1). 
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Discussion. 
 
Existing epidemiologic evidence suggests a seven-fold increase in the incidence of HCC for people 
affected by HIV and hepatitis compared to HIV-negative controls22. The excess risk associated with HIV 
infection has traditionally been explained by the immune-modulatory effects of the virus, leading to a 
faster progression of liver fibrosis23. Consistent with this view, people with HIV-associated HCC present 
at younger age, suggesting a shorter latency of hepatocarcinogenesis compared to their HIV-negative 
counterparts8.  
Once cancer is diagnosed, however, the question as to whether HCC arising in the context of HIV is 
biologically different from other aetiologies has remained unanswered. In absence of evidence to 
demonstrate potential differences at a molecular level, clinical studies evaluating HIV for its prognostic 
role in HCC have led to controversial conclusions, with some studies demonstrating HIV to adversely 
influence the clinical behaviour of HCC and others refuting this prognostic association8-10. 
In this global collaborative study, the largest to have evaluated the clinico-pathologic impact of HIV in 
patients with HCC to date, we demonstrate that HIV infection adversely influences the clinical course 
of HCC, leading to a 24% increase in the hazard of death in patients who did not receive any active 
anticancer treatment.  
A precise estimate of the relationship between HIV and survival in patients with untreated HCC is 
essential to gain insight into the natural history of the disease and establish basic information on 
patients’ prognosis that can be used as a point of reference for future mechanistic and clinical studies.  
By specifically selecting patients who did not receive any effective anti-cancer treatment for HCC we 
intended to rule out the documented confounding effect imposed by the heterogeneity in the provision 
of radical and palliative therapies for HCC and improve the quality of evidence supporting the clinical 
characterisation of HIV-associated HCC.  
A number of previously published studies have confirmed the provision of treatment as a key prognostic 
factor in this population. In the cross-sectional study by Puoti, one of the first to document a negative 
prognostic role of HIV in HCC, 60% of the patients with HIV-associated HCC received best supportive 
care compared to 38% of HIV-negative controls (p=0.02), highlighting that the adverse prognostic role 
of HIV-status might have been at least in part dictated by the diverse treatment allocation across 
groups9. Treatment imbalance is also a feature of the study by Berretta et al., where a significantly 
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higher proportion of HIV+ patients received active anti-cancer treatment (85.6 versus 65.4%, p<0.001). 
However, despite the high proportion of patients qualifying for radical treatments in both groups (44.5 
versus 51.1%, p=0.66), HIV+ patients appear disadvantaged by the inferior likelihood of receiving 
treatment at recurrence (61% versus 86.2%, p<0.001)8. 
Our study cohort, which includes patients from multiple centers across Europe, America and Asia, 
reproduced a balanced distribution of liver functional reserve classes and BCLC stages, showing – 
perhaps unsurprisingly – that the majority of patients who, based on the opinion of the treating 
multidisciplinary team, qualified solely for best supportive care clustered within the more advanced 
BCLC stages of the disease (C-D stage, 75%).  
In attempting to determine the prognostic interaction between HIV and basic clinico-pathologic features 
of HCC, we produced a multivariable regression model of survival to adjust our prognostic estimate for 
key confounders including BCLC stage, CTP class, gender, AFP levels and geographical origin of the 
patients. 
Interestingly, our results show that the effect of HIV-seropositivity impacts on the survival of patients 
with HCC independently from a number of established staging parameters, including BCLC stage. We 
also document the protective effect of female gender18,24 in the prognosis of advanced HCC as well as 
the inherent differences in survival amongst Western and Eastern populations, results that find a strong 
resonance in the HCC literature25. Taken together, these results suggest our patient cohort to be fully 
representative of the broader, contemporary population of HCC patients.  
From an HIV infection standpoint, it is worthy of note that the majority of the HIV+ patients considered 
for this study were HCV-co-infected, on cART at the time of diagnosis and had evidence of acceptable 
CD4 counts and suppressed HIV RNA levels.  
This is in line with previous evidence reporting on incidence and mortality of HCC in PLHIV, where HCV 
co-infection is demonstrated as the predominant risk factor for HCC26, causing a significant increase in 
liver-related mortality even in patients achieving long-term control of the underlying HIV infection3. In 
our study, patients had been on cART for a median duration of 8.3 years. However by choosing cART 
initiation as a measure of duration of HIV infection, we are likely to have underestimated the true latency 
period between HIV/hepatitis co-infection and HCC diagnosis, which typically ranges between 10 to 20 
years27. 
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As a likely consequence of good HIV control, none of the parameters indicative of severity of HIV 
infection (CD4 counts, HIV RNA) revealed prognostic in our cohort of HIV-associated HCC patients, 
where liver functional reserve and AFP levels emerged as the only indicators of worse survival.  
We believe this finding to have important ramifications with regards to the clinical management of 
patients with HIV-associated HCC. Clinical practice has evolved to support an equal-access, unbiased 
environment for the management of HCC in PLHIV10. Whilst patients with HCC and well-controlled HIV 
should face no barriers in the provision of active anti-cancer treatment compared to HIV-negative 
individuals, the inferior probability of survival that accompanies patients with HIV deserves to be taken 
into account in patient counselling and therapeutic decision making. 
Our study emphasizes the predominance of tumour-related factors and hepatic reserve over 
parameters relating to the severity of HIV infection in influencing survival. A number of studies have 
highlighted the complex and multi-factorial pathogenesis of accelerated hepatic fibrosis in patients with 
HIV and hepatitis. Besides viral factors, enhanced gut permeability, metabolic dysregulation of the liver 
microenvironment and high prevalence of concurrent liver-specific noxae including alcohol and drug 
use are factors that might explain the accelerated course of the disease28. In our study, HIV+ patients 
were significantly younger at HCC diagnosis and had evidence of poorer synthetic function and more 
severe portal hypertension as demonstrated by higher ALT/AST levels and lower albumin and platelet 
counts, to suggest that the prognostic imbalance observed might be due to the superadded burden of 
HIV infection in deteriorating patients’ liver functional reserve16. In keeping with this view, the balance 
in tumour staging features and circulating AFP levels observed across the two patient subgroups further 
emphasises the pathophysiologic relevance of the cirrhotic microenvironment over tumour-specific 
features in justifying the excess mortality seen in HIV-associated HCC29, where decompensation of 
cirrhosis is more common and predicts for significantly shorter survival30.  
It has been shown that, particularly in the context of HIV/HCV co-infection, patients with HCC often 
present with infiltrative pattern of growth associated with a faster course of progression and inferior 
likelihood of long-term survival27. Whether HIV infection pre-conditions the efficiency of anti-tumour 
immunity, an emerging prognostic and therapeutically actionable domain in the progression of HCC, is 
presently unknown and should be investigated in future studies.  
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Our study acknowledges a number of limitations. Firstly, the patient population selected for this study 
is mostly represented by patients with advanced-stage HCC, whose natural history is fundamentally 
different from that of patients with early-stage disease31. However, as far as the primary endpoint of the 
study is concerned, BCLC stage was balanced across cases and controls and was accounted for in all 
survival analyses. Interestingly, the survival outcomes reported in the present study consolidate recent 
evidence suggesting that the prognosis of untreated early and intermediate-stage HCC might be 
significantly poorer than previously reported. In the study by Khalaf et al., median OS for BCLC 0/A and 
B patients was in fact 13 and 9 months respectively32, significantly shorter than the 38-, 25- and 10-
months median survival probability previously reported by Giannini et al.  for BCLC 0, A and B stages 
of HCC18. 
Such wide inter-study variability is perhaps unsurprising if one considers the number of potential un-
reported factors that might have influenced survival estimation including co-morbidities, socio-economic 
factors and patients’ preferences. However, these factors are difficult if not impossible to fully account 
for in a global multi-center study where access to care, availability and adherence to screening 
programs as well as quality of palliative care support after diagnosis can be highly heterogeneous 
across healthcare systems. As we are unable to reconstruct the clinical reasons as to why patients did 
not receive effective anti-cancer treatment, we cannot adjust our analysis for the competing effect of 
liver-unrelated comorbidities as predictors of survival. In particular, due to limitations in sample size, we 
were unable to study the prognostic contribution of efficacious treatment for HCV or HBV on the survival 
estimates we reported, a point that should be addressed in future studies. However, the effect of 
comorbidities and prior anti-viral treatment is likely to be fairly small in reality, as the dominant factor 
affecting the mortality of this patient population is tumour progression33.  
In addition, whilst our study was affected by missing data, we explicitly addressed this issue using 
multiple imputation, an approach that relies on the assumption that the data are missing at random 
(MAR), i.e. that — given the observed data — the missingness mechanism does not depend on 
unobserved data. The considerable amount of information available in the dataset (>80 variables) and 
the large sample size (>1500 patients) enabled us to include in the imputation models all variables 
associated with missingness, rendering the MAR assumption likely to hold. 
To conclude, in our global, multi-center collaborative study, we have provided confirmatory evidence to 
show that HIV infection is associated with worse prognosis in a population of patients with HCC where 
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survival estimates were not biased by the effect of treatment. The median overall survival of HIV-
associated HCC patients of 2.2 months reflects the natural history of untreated patients seen in routine 
clinical practice and should be considered a reference point for future studies. Follow-on research 
should explore the prognostic impact of socio-economic factors and co-morbid conditions, two aspects 
that might be unevenly distributed across HIV-positive and negative patients and might relate to the 
difference in survival observed in our study. In parallel, mechanistic studies on clinical samples 
evaluating the immunopathologic features of HIV-associated HCC in comparison with HIV-negative 
controls are urgently required. 
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Figure Legends. 
Figure 1. CONSORT diagram illustrating patient accrual to the study. 
Figure 2. Kaplan-Meier curves illustrating the prognostic relationship of HIV-seropositivity in 
influencing the overall survival of patients with untreated HCC. 
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Table 1. Clinicopathologic features of patients with untreated hepatocellular carcinoma. 
Characteristics 
HIV- 
(N=1456) 
HIV+ 
(N=132) 
P-value 
Age (years), median (IQR) 66.0 (15.79) 52.9 (10.88) <0.0001 a 
Male gender, N (%) 1193 (81.9) 125 (94.7) 0.0003 b 
Continent: Americas/Asia vs Europe, N (%) 861 (59.1) 97 (73.5) 0.0017 b 
Viral aetiology of liver disease, N (%)    
HBV 665 (45.7) 33 (25.0) <0.0001 b 
HCV 540 (37.1) 103 (78.0) <0.0001 b 
Alcohol aetiology of liver disease, N (%) 370 (25.4) 45 (34.1) 0.9112 b 
AFP (ug/L), median (IQR) 351.0 (6878.00) 660.0 (9949.50) 0.1116 a 
Albumin (g/L), median (IQR) 31.0 (9.00) 29.0 (10.00) <0.0001 a 
Bilirubin (umol/L), median (IQR) 27.4 (32.49) 26.4 (42.75) 0.7675 a 
ALT (IU/L), median (IQR) 47.0 (44.00) 56.0 (56.75) 0.0014 a 
AST (IU/L), median (IQR) 95.0 (100.00) 128.0 (111.00) 0.0005 a 
Platelets (10⁹cells/L), median (IQR) 149.0 (138.75) 129.0 (149.50) 0.0675 a 
Performance status, N (%)    
0 431 (29.6) 55 (41.7) 
0.0048 
1 502 (34.5) 32 (24.2) 
2 292 (20.1) 18 (13.6) 
3 116 (8.0) 14 (10.6) 
4 29 (2.0) 5 (3.8) 
BCLC stage, N (%)    
0 15 (1.0) 2 (1.5) 
0.9323 b 
A 158 (10.9) 17 (12.9) 
B 191 (13.1) 16 (12.1) 
C 699 (48.0) 62 (47.0) 
D 372 (25.5) 35 (26.5) 
CTP score, median (IQR) 7.0 (3.00) 7.0 (3.00) 0.4245 a 
CTP class, N (%)    
A 499 (34.3) 40 (30.3) 
0.3435 b B 610 (41.9) 59 (44.7) 
C 288 (19.8) 33 (25.0) 
Maximum diameter of largest lesion (cm), 
median (IQR) 
4.8 (5.00) 5.5 (5.25) 0.0493 a 
Extrahepatic disease, N (%) 604 (41.5) 37 (28.0) 0.0035 b 
Portal vein thrombosis, N (%) 536 (36.8) 47 (35.6) 0.3940 b 
Multinodular disease, N (%) 738 (46.5) 67 (50.8) 0.6947 b 
On antiretroviral treatment, N (%) - 85 (64.4) - 
Duration of antiretroviral treatment (years), 
median (IQR) 
 8.3 (8.59)  
Antiretroviral regimen    
PI - 35 (26.5) - 
NNRTI - 25 (18.9) - 
NRTI - 16 (12.1) - 
INI - 5 (3.8) - 
NNRTI+INI - 1 (0.8) - 
INI+PI - 1 (0.8) - 
Risk factor for HIV, N (%)    
Intravenous drug use - 66 (50.0) - 
Heterosexual contact - 14 (10.6) - 
Homosexual contact - 10 (7.6) - 
Blood products - 3 (2.3) - 
Unknown - 25 (18.9) - 
CD4+ cell count (cells/mm3), median (IQR) - 256.0 (284.00) - 
Undetectable HIV viral load, N (%) - 68 (51.5) - 
Undetectable HBV DNA, N (%) - 6 (4.5) - 
Undetectable HCV RNA, N (%) - 8 (6.1) - 
HCV genotype    
1 - 45 (34.1) - 
2 - 3 (2.3) - 
3 - 5 (3.8) - 
 
a Mann-Whitney test.  b Pearson’s chi-squared test.   
IRQ, interquartile range.  AFP, alpha-fetoprotein.  ALT, Alanine aminotransferase.  AST, Aspartarte 
aminotransferase.  PT, prothrombin time.  BCLC, Barcelona Clinic Liver Cancer.  CTP, Child-Turcotte-
Pugh.  PI, protease inhibitor. NNRTI, non-nucleoside reverse transcriptase inhibitor. NRTI, nucleoside 
reverse transcriptase inhibitor. INI, Integrase inhibitor.  
Please note that the sum of percentages may be lower than 100% owing to missing data.  
Table 2. Effects of HIV+ status and common prognostic factors on overall survival in multiply-imputed 
datasets 
A. In the full sample of HCC patients (N=1,588) 
Predictor 
Univariable models  Multivariable model 
Hazard ratio (95%CI) P-value  Hazard ratio (95%CI) P-value 
HIV+ status 1.49 (1.22 to 1.82) <0.0001  1.24 (1.02 to 1.52) 0.0333 
Male gender 1.62 (1.36 to 1.94) <0.0001  1.34 (1.12 to 1.61) 0.0016 
BCLC stage C/D vs 0/A/B 3.06 (2.57 to 3.65) <0.0001  1.76 (1.44 to 2.13) <0.0001 
CTP class      
B vs A 1.69 (1.45 to 1.97) <0.0001  1.76 (1.50 to 2.06) <0.0001 
C vs A 2.44 (2.04 to 2.93) <0.0001  2.42 (1.98 to 2.95) <0.0001 
Log AFP level (ng/dl) 1.18 (1.16 to 1.21) <0.0001  1.15 (1.12 to 1.17) <0.0001 
Continent: Americas/Asia vs 
Europe 
2.59 (2.24 to 3.00) <0.0001  1.92 (1.63 to 2.25) <0.0001 
 
B. In HIV+ HCC patients (N=132)  
Predictor 
Univariable models  Multivariable model 
Hazard ratio (95%CI) P-value  Hazard ratio (95%CI) P-value 
BCLC stage C/D vs 0/A/B 1.58 (1.01 to 2.46) 0.0441  1.38 (0.82 to 2.31) 0.2226 
CTP class      
B vs A 1.67 (0.86 to 3.26) 0.1331  1.43 (0.72 to 2.86) 0.3048 
C vs A 3.45 (1.72 to 6.92) 0.0005  2.78 (1.31 to 5.91) 0.0079 
Log AFP level (ng/dl) 1.20 (1.11 to 1.31) <0.0001  1.18 (1.09 to 1.28) <0.0001 
CD4+ cell count (x 100) 0.93 (0.83 to 1.04) 0.1914  0.96 (0.85 to 1.08) 0.4689 
Log HIV viral load 
(copes/ml) 
1.02 (0.96 to 1.08) 0.6126  0.99 (0.92 to 1.06) 0.7124 
Continent: Americas/Asia 
vs Europe 
1.09 (0.70 to 1.69) 0.7154  0.90 (0.55 to 1.46) 0.6666 
 
BCLC, Barcelona Clinic Liver Cancer.  CTP, Child-Turcotte-Pugh.  AFP, alpha-fetoprotein. 
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Supplementary Methods 
 
Multiple imputation procedures 
Due to the considerable proportion of missing data for some variables in the analysis datasets (up to 
~50% for the full dataset of 1588 patients and up to ~ 90% for the subset of 132 HIV+ patients with HIV-
related phenotypes), we used a multiple imputation with chained equations (MICE) approach assuming 
that the data in were missing at random (MAR). 
We imputed each dataset separately to allow for imputation of HIV-related prognostic factor. For both 
the full dataset of 1588 patients and the subset of 132 HIV+ patients, we included in the imputation 
models (i) all predictors of missingness (log-likelihood p <0.10) for any of the variables included in the 
initial analysis models specified in the following paragraph “Backward selection procedures”, (ii) the 
event indicator (subject alive/death), and (iii) the Nelson-Aalen estimator of baseline hazard(1). From 
each original dataset, we generated 100 imputed datasets to provide stable estimates. Diagnostics 
plots of trace lines revealed satisfactory convergence of imputation models. Plots of imputed values vs 
the observed values suggested that imputed values were plausible. 
 
Backward selection procedures 
We applied a backward selection algorithm on the imputed datasets following the “Rubin rule” 
approach(2). For each step, a Cox regression model was fitted in the imputed datasets and parameter 
estimates were averaged as per Rubin rule. The backward selection algorithm stopped when all pooled 
estimates from the multiply-imputed datasets had a p-value lower than 0.05. 
In the full sample (N=1588) of all untreated HCC patients, the initial multivariable Cox model comprised 
age, gender, BCLC stage, CTP class, log-transformed AFP, year of HCC diagnosis, a binary variable 
representing continent of study centre (Americas/Asia vs Europe), and HIV status. After three steps, 
backward selection identified the following prognostic factors associated with OS in the full dataset: 
HIV, gender, BCLC stage, CTP class, log-transformed AFP, and continent. 
In the subset (N=132) of HIV+ untreated HCC patients, the initial model comprised factors associated 
to OS in HIV+ patients(3, 4) in addition to common prognostic factors for HCC: age, BCLC stage, CTP 
class, log-transformed AFP, CD4+ concentration, year of HCC diagnosis, continent, CD4+ 
concentration, log-transformed HIV viral load, presence of antiretroviral treatment. This initial model 
could not include gender as only 2/132 patients were female. After eight steps, two parameters were 
associated to OS at the 5% level of significance in the subset of HIV+ patients: CTP class and log-
transformed AFP. We re-added common prognostic factor for HCC and HIV  as well as continent owing 
to its significance in the full-sample analysis, so that the final model for HIV+ patients included: CTP 
class, BCLC stage, log-transformed AFP, HIV viral load, CD4+ concentration, and continent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary tables and figures 
 
Supplementary Table 1. Complete-case analyses: effects of HIV+ status and selected prognostic 
factors on survival 
A. In the full sample of HCC patients (N=1588) 
Predictor 
Univariable models   Multivariable model  
Hazard ratio (95%CI) P-value N  Hazard ratio (95%CI) P-value N 
HIV+ status 1.49 (1.22 to 1.82) <0.0001 1,588  1.23 (1.00 to 1.51) 0.0515 
1,463 
Male gender 1.62 (1.35 to 1.93) <0.0001 1,586  1.29 (1.07 to 1.56) 0.0071 
BCLC stage C/D vs 
0/A/B 
3.09 (2.59 to 3.69) <0.0001 1,567  1.85 (1.52 to 2.26) <0.0001 
CTP class       
B vs A 1.63 (1.40 to 1.90) <0.0001 1,529 
 
 1.76 (1.51 to 2.05) <0.0001 
C vs A 2.35 (1.97 to 2.82) <0.0001  2.42 (1.99 to 2.95) <0.0001 
Log AFP 1.19 (1.16 to 1.21) <0.0001 1,538  1.15 (1.12 to 1.17) <0.0001 
Continent: 
Americas/Asia vs 
Europe 
2.59 (2.24 to 3.00) <0.0001 1,588  2.01 (1.71 to 2.38) <0.0001 
 
A. In HIV+ HCC patients (N=132) 
Predictor 
Univariable models   Multivariable model  
Hazard ratio (95%CI) P-value N  Hazard ratio (95%CI) P-value N 
BCLC stage C/D vs 
0/A/B 
1.58 (1.01 to 2.46) 0.0441 132  1.56 (0.90 to 2.69) 0.1141 
118 
CTP class       
B vs A 1.67 (0.86 to 3.26) 0.1331 
132 
 1.49 (0.73 to 3.04) 0.2739 
C vs A 3.45 (1.72 to 6.92) 0.0005  2.40 (1.07 to 5.39) 0.0344 
Log AFP 1.21 (1.12 to 1.32) <0.0001 125  1.20 (1.10 to 1.30) <0.0001 
CD4 count (x 100) 0.92 (0.83 to 1.02) 0.1329 129  0.96 (0.85 to 1.08) 0.4755 
Log viral load 1.02 (0.96 to 1.08) 0.5963 125  0.98 (0.91 to 1.05) 0.5401 
Continent: 
Americas/Asia vs 
Europe 
1.09 (0.70 to 1.69) 0.7154 132  0.69 (0.42 to 1.13) 0.1359 
 
BCLC, Barcelona Clinic Liver Cancer.  CTP, Child-Turcotte-Pugh.  AFP, alpha-fetoprotein. 
 
  
Supplementary Table 2. Distribution of demographic and prognostic characteristics by continent 
 
Characteristics 
Americas/Asia  
(N=958) 
Europe  
(N=630) 
P-value 
Age (years), median (IQR) 62.8 (17.20) 67.0 (14.00) <0.0001 a 
Male gender, N (%) 844 (88.1) 474 (75.2) <0.0001 b 
Survival (months), median (IQR) 2.8 (4.99) 7.0 (13.00) <0.0001 a 
HIV+ status, N (%) 97 (10.1) 35 (5.6) 0.0017 b 
Viral aetiology of liver disease, N (%)    
HBV 544 (56.8) 154 (24.4) <0.0001 b 
HCV 254 (26.5) 389 (61.7) <0.0001 b 
Alcohol aetiology of liver disease, N (%) 189 (19.7) 226 (35.9) <0.0001 b 
BCLC stage, N (%)    
0 5 (0.5) 12 (1.9) 
<0.0001 b 
A 72 (7.5) 103 (16.3) 
B 66 (6.9) 141 (22.4) 
C 610 (63.7) 151 (24.0) 
D 184 (19.2) 223 (35.4) 
CTP score, median (IQR) 7.0 (3.00) 7.0 (3.00) 0.0495 a 
CTP class, N (%)    
A 295 (30.8) 244 (38.7) 
0.0014 b B 428 (44.7) 241 (38.3) 
C 176 (18.4) 145 (23.0) 
AFP (ug/L), median (IQR) 1361.8 (15019.30) 51.0 (840.00) <0.0001 a 
Year of HCC diagnosis, median (IQR) 1996.0 (9.00) 2000.0 (10.00) <0.0001 a 
Cirrhosis, N (%) 230 (24.0) 616 (97.8) <0.0001 b 
Extrahepatic disease, N (%) 594 (62.0) 47 (7.5) <0.0001 b 
Portal vein thrombosis, N (%) 414 (43.2) 169 (26.8) <0.0001 b 
 
a Mann-Whitney test.  b Pearson’s chi-squared test.   
IRQ, interquartile range.  AFP, alpha-fetoprotein.  BCLC, Barcelona Clinic Liver Cancer.  CTP, Child-
Turcotte-Pugh. 
Please note that the sum of percentages may be lower than 100% owing to missing data. 
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